Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zunsemetinib in Moderate-to-Severe Active Psoriatic Arthritis
NCT05511519Phase 2Terminated
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of zunsemetinib in psoriatic arthritis (PsA), sponsored by Aclaris Therapeutics, Inc.. Started Jul 2022; status: terminated.
02
Drugs
zunsemetinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05511519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05511519.